Mereo Biopharma Group Plc ADR (NASDAQ:MREO) price on current trading day, rose 7.95% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.90.
A look at the stock’s price movement, the close in the last trading session was $1.76, moving within a range at $1.575 and $1.935. The beta value (5-Year monthly) was 0.654. Turning to its 52-week performance, $5.02 and $1.70 were the 52-week high and 52-week low respectively. Overall, MREO moved -24.30% over the past month.
Mereo Biopharma Group Plc ADR’s market cap currently stands at around $294.78 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-25.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend MREO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MREO’s current price about -17.75% and -26.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.06, while 7-day volatility ratio is 14.91% and 8.36% in the 30-day chart. Further, Mereo Biopharma Group Plc ADR (MREO) has a beta value of 0.66, and an average true range (ATR) of 0.20. Analysts have given the company’s stock an average 52-week price target of $7.5, forecast between a low of $4 and high of $8. Looking at the price targets, the low is -110.53% off current price level while to achieve the yearly target high, price needs to move -321.05%. Nonetheless, investors will most likely welcome a -294.74% jump to $7.5 which is the analysts’ median price.
If we refocus on Mereo Biopharma Group Plc ADR (NASDAQ:MREO), historical trading data shows that trading volumes averaged 2.06 over the past 10 days and 1.36 million over the past 3 months. The company’s latest data on shares outstanding shows there are 155.15 million shares.
The 9.96% of Mereo Biopharma Group Plc ADR’s shares are in the hands of company insiders while institutional holders own 66.28% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.03 million on 2025-03-14, giving us a short ratio of 3.82. The data shows that as of 2025-03-14 short interest in Mereo Biopharma Group Plc ADR (MREO) stood at 459.99999999999994 of shares outstanding, with shares short falling to 7.26 million registered in 2025-02-14. Current price change has pushed the stock -45.71% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MREO stock continues to rise going into the next quarter.
